文献速递系统性红斑狼疮

贝利尤单抗在儿童与成人系统性红斑狼疮中的疗效与安全性:跨研究比较

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
PubMed 文献 · RMD Open · 2021-01-01

该研究通过跨研究比较PLUTO(儿童II期)与BLISS-52、BLISS-76、BLISS-NEA、EMBRACE(成人III期)中接受贝利尤单抗或安慰剂联合标准治疗的活动性SLE患者,评估52周SRI-4应答率、SRI-6应答率、首次严重复发时间及安全性。结果显示儿童与成人研究间SRI-4应答率相似,贝利尤单抗组均高于安慰剂组,且降低严重复发风险,不良事件发生率各研究间相似。

要点

  • 贝利尤单抗联合标准治疗在儿童与成人SLE中SRI-4应答率相似且均优于安慰剂。
  • 基线SELENA-SLEDAI≥10的患者SRI-4应答率普遍高于≤9的患者。
  • 贝利尤单抗在所有研究中均降低严重复发风险,不良事件发生率相似。

核心结论

  • 贝利尤单抗联合标准治疗在儿童与成人SLE患者中显示出一致的疗效与安全性。

研究设计与样本

  • 跨研究比较PLUTO(儿童II期)与BLISS-52、BLISS-76、BLISS-NEA、EMBRACE(成人III期)中接受贝利尤单抗或安慰剂联合标准治疗的活动性SLE患者。
  • 安全性数据比较还纳入成人LBSL02(II期)和BLISS-SC(III期)研究。

主要发现

  • SRI-4应答率在儿童与成人研究间相似,贝利尤单抗组均高于安慰剂组(PLUTO:52.8% vs 43.6%;BLISS-52:57.6% vs 43.6%;BLISS-76:43.2% vs 33.8%;BLISS-NEA:53.8% vs 40.1%;EMBRACE:48.7% vs 41.6%)。
  • 所有研究中基线SELENA-SLEDAI评分≥10的患者SRI-4应答率普遍高于基线评分≤9的患者。
  • 贝利尤单抗组SRI-6应答率在各研究间相似(PLUTO:41.2%;BLISS-52:46.2%;BLISS-76:33.1%;BLISS-NEA:43.9%;EMBRACE:37.5%)。
  • 贝利尤单抗在所有研究中均降低严重复发风险(基于SELENA-SLEDAI复发指数)。
  • 不良事件发生率在所有研究中相似。

关键数值与推荐

  • 主要疗效指标为第52周SRI-4应答率(EMBRACE采用改良SLEDAI蛋白尿评分的SRI-S2K)。
  • 次要疗效指标包括第52周SRI-6应答率及52周内首次严重复发时间。

临床怎么用

  • 贝利尤单抗联合标准治疗可用于儿童和成人活动性SLE患者,疗效与安全性在两组间一致。
  • 基线疾病活动度较高(SELENA-SLEDAI≥10)的患者可能从贝利尤单抗治疗中获益更明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy and safety of belimumab in paediatric versus adult patients with systemic lupus erythematosus (SLE). METHODS: We performed across-study comparisons of patients with active SLE who received belimumab or placebo, plus standard therapy, in PLUTO (paediatric phase II) and BLISS-52, BLISS-76, BLISS-NEA and EMBRACE (adult phase III). Analysed efficacy data included Week 52 SLE Responder Index (SRI)-4 response rate (EMBRACE: SRI with modified Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) proteinuria scoring (SRI-S2K)); SRI-4 response rate (EMBRACE: SRI-S2K) according to baseline disease activity indicators (Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score; anti-dsDNA/C3/C4 levels); Week 52 SRI-6 response rate; and time to first severe flare (SELENA-SLEDAI Flare Index) over 52 weeks. Safety data were compared for all aforementioned studies along with adult LBSL02 (phase II) and BLISS-SC (phase III). RESULTS: SRI-4 response rates were similar across the paediatric and adult studies; more belimumab-treated patients achieved SRI-4 responses versus placebo (PLUTO: 52.8% vs 43.6%; BLISS-52: 57.6% vs 43.6%; BLISS-76: 43.2% vs 33.8%; BLISS-NEA: 53.8% vs 40.1%; EMBRACE: 48.7% vs 41.6%). Across all studies, SRI-4 response rates were generally greater in patients with baseline SELENA-SLEDAI scores ≥10 than in patients with baseline SELENA-SLEDAI scores ≤9. A similar proportion of belimumab-treated patients achieved SRI-6 across all studies (PLUTO: 41.2%; BLISS-52: 46.2%; BLISS-76: 33.1%; BLISS-NEA: 43.9%; EMBRACE: 37.5%). Belimumab reduced the risk of severe flare versus placebo in all studies. The incidence of adverse events was similar across all studies. CONCLUSIONS: These analyses demonstrate consistent efficacy and safety of belimumab plus standard therapy across paediatric and adult patients with SLE. TRIAL REGISTRATION NUMBERS: PLUTO (NCT01649765); BLISS-52 (NCT00424476); BLISS-76 (NCT00410384); BLISS-NEA (NCT01345253); EMBRACE (NCT01632241); BLISS-SC (NCT01484496); and LBSL02 (NCT00071487).

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Brunner HI, Abud-Mendoza C, Mori M, et al. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 2021. PMID: 34531304. doi:10.1136/rmdopen-2021-001747

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。